Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 extension study in adults with refractory focal onset epilepsy
NL-OMON60072Phase 2Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opakalim in Focal Onset Epilepsy, sponsored by Biohaven Ltd. Primary endpoint: Safety and tolerability. Started Aug 2025; status: recruiting.
02
Drugs
opakalim
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON60072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60072.